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To identify human proteins that bind to the Smac and
caspase-9 binding pocket on the baculoviral inhibitor of
apoptosis protein (IAP) repeat 3 (BIR3) domain of hu-
man XIAP, we used BIR3 as an affinity reagent, followed
by elution with the BIR3 binding peptide AVPIA, micro-
sequencing, and mass spectrometry. The mature serine
protease Omi (also known as HtrA2) was identified as a
mitochondrial direct BIR3-binding protein and a
caspase activator. Like mature Smac (also known as
Diablo), mature Omi contains a conserved IAP-binding
motif (AVPS) at its N terminus, which is exposed after
processing of its N-terminal mitochondrial targeting se-
quence upon import into the mitochondria. Mature Omi
is released together with mature Smac from the mito-
chondria into the cytosol upon disruption of the outer
mitochondrial membrane during apoptosis. Finally, ma-
ture Omi can induce apoptosis in human cells in a
caspase-independent manner through its protease ac-
tivity and in a caspase-dependent manner via its ability
to disrupt caspase-IAP interaction. Our results provide
clear evidence for the involvement of a mitochondrial
serine protease in the apoptotic pathway, emphasizing
the critical role of the mitochondria in cell death.
The IAP1 proteins were first identified from baculoviruses as
proteins that function to suppress host cell death upon viral
infection (1). More recently, IAPs were found in mammals,
insects, nematodes, and yeast (1–3). All IAPs share one or more
signature motifs, referred to as BIRs, that are essential for the
antiapoptotic activity associated with these proteins. The BIR
motifs have been shown to bind directly to caspases and to
inhibit their activity (2, 4). In the insect Drosophila melano-
gaster, three proteins known as Reaper, Hid, and Grim have
been identified as direct IAP-binding proteins that promote
caspase activation by binding to the BIR domain of IAPs and
disrupting IAP-caspase interaction (5–7). Although Smac/Dia-
blo does not share sequence homology with these proteins ex-
cept for the first four N-terminal residues, which constitute its
IAP-binding motif (8, 9), it is the only known mammalian
functional homolog of these proteins with a similar mode of
action. Smac promotes caspase activation and apoptosis by
binding to the BIR3 and BIR2 domains of XIAP and disrupting
its interaction with caspase-9 and the effector caspases
(caspase-3 and -7) (8–10). Since the mechanism of IAP inhibi-
tion of caspases is conserved in mammals and insects, it is
expected that other mammalian IAP-binding proteins are still
undiscovered. In this report, we identified the serine protease
Omi/HtrA2 as a mitochondrial direct IAP-binding protein,
which is released from the mitochondria upon induction of
apoptosis by apoptotic stimuli. Like Smac, the mature Omi
protein contains a conserved IAP-binding motif (AVPS) at its N
terminus. We demonstrate that deregulated expression of Omi
in the cytoplasm of mammalian cells induces apoptosis in these
cells, indicating that Omi could participate in the mitochon-
drial apoptotic pathway.
EXPERIMENTAL PROCEDURES
Affinity Purification of Omi from Human 293 Cells—5 ml of 293 cell
pellet was washed once in phosphate-buffered saline (10 mM phosphate,
pH 7.4, containing 150 mM NaCl) and centrifuged, and the pellet was
resuspended in 10 ml of cell lysis buffer (20 mM Tris-HCl, pH 7.4, 150
mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA supplemented
with protease inhibitor mix (Sigma P-8340) containing 4-(2-amino-
ethyl)-benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin,
and aprotinin). Cells were homogenized and centrifuged once at
20,000  g, and the supernatant was then subjected to centrifugation at
100,000  g. The resultant supernatant was precleared with glutathi-
one-Sepharose beads and then incubated with GST-BIR3 bound to
glutathione-Sepharose beads for 12 h at 4 °C. The mixture was centri-
fuged at 500 rpm for 3 min, and the GST-BIR3 bead pellet was washed
three times in the lysis buffer. The GST-BIR3-bound proteins were
eluted with 200 M AVPIA-Smac peptide at 37 °C for 1 h and then
analyzed by Far Western blotting with 35S-labeled in vitro translated
XIAP as described below.
cDNA Cloning and Expression of Recombinant Proteins—The full-
length human Omi cDNA clone was obtained from the IMAGE consor-
tium (GenBankTM accession number AI979237). Constructs encoding
full-length Omi or truncated mutants were generated by PCR using
modified complementary PCR adapter primers. C-terminal FLAG
epitope tagging was done by cloning the PCR-generated Omi cDNAs in
frame into FLAG-C-pCDNA3. Plasmids encoding GFP fusion proteins
were constructed using pEGFP-N1 (CLONTECH). Full-length XIAP
and its BIR3-RING (residues 243–497) domain were overexpressed in
E. coli strain DH5 as N-terminally GST-tagged proteins using a pGEX
4T vector (Amersham Biosciences, Inc.). Full-length XIAP, cIAP1, and
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cIAP2 were in vitro translated in the presence of [35S]methionine in
reticulocyte lysates using MYC-pcDNA3 constructs. Mature Smac or
Omi and its mutants were overexpressed in Escherichia coli strain
BL21(DE3) as C-terminally GST- or His6-tagged proteins using a pET-
28-GST or pET-28 vector, respectively.
Subcellular and Submitochondrial Fractionation—Cells were ho-
mogenized in buffer A (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl2,
1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM dithiothreitol, 0.1 mM
phenylmethylsulfonyl fluoride, with protease inhibitor mix). The homo-
genate was centrifuged at 800  g. Nuclei were prepared from the crude
nuclear pellet as described before (11). The supernatant was centri-
fuged at 10,000  g, and the resultant pellet was further processed for
mitochondria purification over a Percoll gradient. The postmitochon-
drial supernatant was subjected to 100,000  g, and the microsomal
pellet and cytosolic supernatants were collected separately. Subfrac-
tionation of mitochondria by digitonin was carried out as described
before (12).
Far Western Blotting—Affinity-purified proteins or cellular extracts
were subjected to SDS-PAGE and then transferred to nitrocellulose
membrane using a standard Western blotting technique. The proteins
on the membrane were probed with 35S-labeled in vitro translated XIAP
as described before (9).
Cell Death Assays—The ability of Omi to potentiate staurosporine-
induced apoptosis (Fig. 4c) was assayed by transfecting human HeLa
cells (1  105 cells/well) in six-well plates with 0.3 g of pEGFP-N1
reporter plasmid (CLONTECH), 1.2 g of empty vector, or a construct
encoding C-terminally FLAG-tagged Omi precursor using the Lipo-
fectAMINE™ method. Cells were treated with increasing concentra-
tions of staurosporine (0–2.5 M) for 7 h. Cells were stained with
propidium iodide and 4,6-diamidino-2-phenylindole stains. Normal
and apoptotic GFP-expressing cells were counted using fluorescence
microscopy. The percentage of apoptotic cells in each experiment was
expressed as the mean percentage of apoptotic cells as a fraction of the
total number of GFP-expressing cells. The ability of mature Omi to
potentiate TRAIL-induced apoptosis (Fig. 6f) was assayed by transfect-
ing human MCF-7 cells (1  105 cells/well) in six-well plates with 1.2 g
of GFP-IETD-Omi expression construct or pEGFP-N1 plasmid. 24 h
after transfection, cells were treated with TRAIL (0.25 g/ml) for 16 h,
and the percentages of GFP-positive, 4,6-diamidino-2-phenylindole-
positive apoptotic cells were determined as above. Similar assays were
performed to determine the ability of M-Omi-GFP proteins to induce
apoptosis in MCF-7 cells or Apaf / or caspase-9 / mouse embryo
fibroblasts.
Immunofluorescence Confocal Microscopy—Cells were grown on cov-
erslips and then stained with a polyclonal antibody raised against pure
mature recombinant Omi protein and a mouse anti-Smac monoclonal
antibody after fixing the cells with 4% paraformaldehyde. Fluorescein
isothiocyanate-conjugated anti-rabbit and rhodamine-conjugated anti-
mouse antibodies were used as secondary antibodies. After staining, the
coverslips were mounted on slides and observed using confocal
microscopy.
In Vitro Interaction Assays—All in vitro interactions were performed
as described recently (8–10).
RESULTS AND DISCUSSION
To identify novel IAP binding proteins, we used a GST-BIR3
fusion protein as an affinity reagent to purify new IAP-binding
proteins from extracts of human 293 cells and mouse tissues.
After binding the extracts to the GST-BIR3 protein, the bound
proteins were eluted with the IAP-binding motif peptide AV-
PIA and analyzed by Far Western blotting with 35S-labeled
FIG. 1. Identification of Omi as a BIR3-binding protein. a, extracts from HEK293 cells or mouse heart, kidney, liver, or spleen tissues were
bound to GST-BIR3 fusion protein, and the bound proteins were eluted with the Smac AVPIA peptide. The AVPIA peptide eluates were
fractionated by SDS-PAGE and then Far Western blotted with 35S-labeled XIAP (upper panel) or immunoblotted with a Smac monoclonal antibody
(lower panel). b, Coomassie-stained gel of the GST-BIR3 affinity-purified proteins. The 23-, 38-, and 80-kDa bands were excised from the gel and
subjected to automated microsequencing followed by mass spectrometry. The band immediately below the 80-kDa band was identified as Hsp70.
c, 293-T cells were transfected with an Omi precursor expression construct (Omi lane) or empty vector (vector lane), and their extracts were
fractionated by SDS-PAGE and then Far Western blotted with 35S-labeled XIAP (left panel) or immunoblotted with Smac antibody (middle panel)
or an Omi polyclonal antibody (right panel). First lane, GST-BIR3 affinity-purified proteins from 293 cells. A small amount of the unprocessed Omi
precursor protein can be seen in the Omi lane. d, 293 cellular extracts were either left untreated (Undepleted lane) or depleted with Smac antibody
(Depleted lane), and the extracts were bound to GST-BIR3 fusion protein and analyzed as in a. The antibody-bound proteins (Ab pellet) were also
fractionated and subjected to the same analyses. Last lane, 293 cellular extracts were bound to the E314S mutant GST-BIR3 fusion protein, and
the bound proteins were analyzed as in a. An asterisk indicates nonspecific bands. An arrow indicates the IgG band.















XIAP. Three proteins, migrating as 23-, 38-, and 80-kDa bands,
that specifically interact with the 35S-labeled XIAP, were de-
tected in the AVPIA peptide eluates from the human 293 cells
and the mouse tissues (Fig. 1a). A large scale affinity prepara-
tion was then fractionated on an SDS-polyacrylamide gel (Fig.
1b), and the three bands were cut and subjected to microse-
quencing. Due to the low level of the 80-kDa protein in this
preparation, limited N-terminal sequence information was ob-
tained, which was not sufficient for protein identification. The
N-terminal sequence information of the other two proteins
revealed that the 23-kDa protein is mature Smac/Diablo (13,
14), whereas the 38-kDa band is a previously described serine
protease named Omi or HtrA2 (15, 16) (GenBankTM accession
number XM_002750). Mass spectrometric peptide mass finger-
printing of these two protein bands confirmed the microse-
quencing results. Furthermore, Western blot analysis of the
AVPIA peptide eluates using Smac and Omi antibodies con-
firmed that the 23-kDa band represents Smac and the 38-kDa
band represents Omi (Fig. 1, a and c).
To confirm that Omi associates directly with the BIR3 do-
main of XIAP but not with the Smac protein, we depleted Smac
from the 293 extracts with a Smac monoclonal antibody, bound
the depleted extracts to the GST-BIR3 protein, and then ana-
lyzed the bound proteins by Far Western with 35S-XIAP and
Western blotting with the Smac antibody. Depletion of Smac
did not remove Omi from the 293 extracts, indicating that Omi
binds independently to the GST-BIR3 protein (Fig. 1d). More-
over, Omi, Smac, and the 80-kDa protein did not bind to the
GST-BIR3-E314S mutant (Fig. 1d, last lanes). This mutation
has been shown to abolish binding of Smac and caspase-9 to
BIR3 (8, 9, 17). These results indicate that Omi, Smac, and the
80-kDa protein associate directly with the Smac binding pocket
on the BIR3 of XIAP.
The BIR3 affinity-purified Omi starts with an amino-termi-
nal AVPS sequence, which represents a conserved IAP-binding
motif (Fig. 2A). Based on the deduced amino acid sequence of
the cloned Omi protein (15, 16), this motif is located at residue
134, suggesting that Omi is made as a precursor protein that
undergoes proteolytic processing at residue 133 to remove the
N-terminal leader sequence. To determine whether a recombi-
nant Omi lacking the first 133 residues (mature Omi) can
interact with the GST-BIR3 fusion protein, we expressed this
protein with a C-terminal His6 tag in bacteria and purified it to
apparent homogeneity (Fig. 2b, right panel). N-terminal amino
acid sequencing of the recombinant proteins indicated that the
initiator methionine is removed. Both recombinant mature
Omi and Smac were able to interact equally with the wild type
GST-BIR3 protein but not with the GST-BIR3-E314S mutant
(Fig. 2b, left panel). Mature Omi and Smac were also able to
interact with the GST-BIR1,2 fusion protein. Mutation of the
active site Ser306 to Ala of mature Omi did not affect its inter-
action with GST-BIR3. However, deletion of the AVPS motif of
mature Omi completely abolished its interaction with the GST-
BIR3 fusion protein. Mature Omi can also interact with endog-
enous XIAP in transfected 293 cells (Fig. 2d, upper panel) and
requires the AVPS motif, since mutation of this motif to AAAS
abolished its interaction with the endogenous XIAP. Interest-
ingly, mutation of the AVPS motif to AAAS did not affect the
processing and removal of the N-terminal leader sequence of
the transfected Omi precursor but completely prevented the
interaction with endogenous XIAP (Fig. 2d, middle panel). In
vitro interaction assays revealed that mature Omi could also
FIG. 2. The N terminus of mature Omi harbors an IAP-binding motif. a, bar diagram representing the structure of the Omi precursor and
the location of the AVPS motif. Lower panel, colinear alignment of the N-terminal sequences of Drosophila Reaper, Grim, and Hid and human
caspase-9-p12, Smac, and Omi. The IAP-binding motif is highlighted. b, left panel, Coomassie-stained gel of purified C-terminally His6-tagged
recombinant wild type mature Omi (WT), Omi-AVPS, Omi-S306A, and mature Smac. Right panel, The recombinant Omi and Smac proteins were
bound to GST-BIR1,2, GST-BIR3, or GST-BIR3-E314S fusion proteins, and the bound proteins were fractionated by SDS-PAGE and stained by
Coomassie Blue. c, interaction of XIAP, cIAP1, and cIAP2 with mature Omi and Smac. C-terminal His6-tagged mature Omi, Omi-AVPS, or Smac
or GST protein were immobilized onto Talon affinity resin. The bound resins were incubated with in vitro translated 35S-labeled XIAP, cIAP1, or
cIAP2; washed extensively; and then analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. GST was used as a negative
control (second lane). Fourth panel, Coomassie-stained gel of the immobilized proteins. d, 293T cells were transfected with constructs encoding
C-terminal FLAG-tagged Omi wild type or mutant precursors. 36 h after transfection, Omi was immunoprecipitated by FLAG antibody, and the
immune complex was analyzed by Western blotting with an XIAP monoclonal antibody (upper panel) or FLAG antibody (middle panel). Lower
panel, total extracts probed with the XIAP antibody. A short isoform of XIAP (sXIAP) was also detected with this antibody. The arrows indicate
IgG bands.















interact with cIAP1 and cIAP2 (Fig. 2c). The above data indi-
cate that Omi is a bona fide IAP-binding protein with an
N-terminal IAP binding motif essential for its ability to bind
IAPs.
Computer analysis using the PSORT program revealed that
the N-terminal leader sequence of the Omi precursor contains
within its first 60 residues a typical mitochondrial targeting
sequence. This sequence might be removed by mitochondrial
processing peptidases upon import into the mitochondria. To
examine whether the endogenous mature Omi protein is in-
deed localized in the mitochondria, we subfractionated 293
cells into cytosolic, mitochondrial, microsomal, and nuclear
fractions and bound each fraction to the GST-BIR3 protein. As
shown in Fig. 3a, Far Western and Western blot analyses with
35S-XIAP and Smac and Omi antibodies, respectively, showed
the majority of Omi and Smac to be localized in the mitochon-
drial fraction. Next we subfractionated purified mitochondria
from HEK293 cells into intermembrane space and matrix frac-
tions using 1–1.2% digitonin, which specifically disrupts the
outer mitochondrial membrane without affecting the inner mi-
tochondrial membrane. The fractions were analyzed by immu-
noblotting with Omi and Smac antibodies. Both Omi and Smac
were predominantly present in the intermembrane space frac-
tion (Fig. 3b).
Immunofluorescence confocal microscopy of MCF-7 cells
stained with Omi- and Smac-specific antibodies revealed that
the endogenous Omi and Smac proteins colocalize with each
other and exhibit punctate perinuclear staining characteristic
of mitochondrial localization (Fig. 3c). To confirm the mitochon-
drial localization of Omi, we transfected MCF-7 cells with a
C-terminal GFP-tagged Omi precursor construct. The ectopi-
cally transfected Omi precursor exhibited punctate mitochon-
drial fluorescence (Fig. 3d, right panel). The removal of the
mitochondrial targeting sequence of Omi resulted in the ex-
pression of mature Omi (residues 134–458) in the cytoplasm
(Fig. 3d, middle panel). The first 60 residues of the Omi pre-
cursor, which harbors the MTS, was sufficient for targeting
RFP to the mitochondria when expressed as a fusion protein
with RFP (Fig. 3e). Taken together, the above data indicate
that Omi colocalizes with Smac in the intermitochondrial mem-
brane space.
To determine whether Omi is released together with Smac
and cytochrome c from the mitochondria to the cytoplasm dur-
ing apoptosis, we treated Jurkat and HL-60 cells with stauro-
sporine, which is known to induce the mitochondrial apoptotic
pathway, and analyzed their cytosolic extracts by immunoblot
analysis. As shown in Fig. 4a, cytochrome c, Smac, and Omi
accumulated in the cytosol of these cells in a time-dependent
manner after treatment with staurosporine. Processing of pro-
caspase-3 also followed a similar time course, with maximum
processing observed at 6–8 h after treatment. Very little or no
Omi or Smac proteins nor processing of procaspase-3 was de-
tected in the extracts at zero time points. Similar results were
obtained after treatment of Jurkat cells with TRAIL (Fig. 4b).
Immunofluorescence confocal microscopy of staurosporine-
treated HeLa cells or TRAIL-treated MCF-7 cells showed dif-
fused Immunofluorescence staining of Omi, whereas in the
untreated control cells it is mostly punctate and perinuclear
(Fig. 4c). The above data clearly show that Omi is released
together with cytochrome c and Smac during apoptosis.
FIG. 3. Omi is localized in the mitochondria. a, 293T cells were fractionated into nuclear, mitochondrial, microsomal, and cytosolic fractions.
The nuclear, mitochondrial, and microsomal fractions were lysed in a hypotonic buffer, and the soluble proteins bound to GST-BIR3 fusion protein
and were analyzed as in the legend to Fig. 1a. The same Far Western blot (upper panel) was then probed with Omi and Smac antibodies (second
and third panels, respectively). Total subcellular fractions were also immunoblotted with antibodies against cytochrome c oxidase (fourth panel),
poly(ADP-ribose) polymerase (fifth panel), and -actin (sixth panel). b, purified mitochondria from 293 cells were treated with a buffer containing
1.2% digitonin, and the supernatant and mitoplasts (pellet) were then analyzed by Western blotting with Omi, Smac, and cytochrome c oxidase
antibodies. c, immunofluorescence confocal microscopy of MCF-7 cells stained with Omi-specific (middle panel, green) and Smac-specific (left panel,
red) antibodies. d, confocal micrographs of MCF-7 cells transfected with GFP (left panel) or C-terminal GFP-tagged mature Omi (Omi134–458-
GFP; middle panel) or Omi precursor (Omi-GFP; right panel). e, confocal micrographs of MCF-7 cells transfected with C-terminal RFP-tagged
Omi1–60 (Omi-MTS-RFP; left panel) and pEYFP-Mito marker (middle panel). The right panels in c and e represent merged micrographs.















The ability of TRAIL to induce release of Omi from the
mitochondria of MCF-7 and Jurkat cells suggests that tBid,
which is generated by active caspase-8 after TRAIL-receptor
ligation, is responsible for the release of Omi. To test this
hypothesis, we incubated isolated mitochondria with a physio-
logical amount of tBid. As shown in Fig. 4d, tBid induced
release of Omi, Smac, and cytochrome c from the mitochondria
into the supernatants. Combined, the above data clearly show
that Omi is released from the mitochondria together with cy-
tochrome c and Smac during apoptosis and after stimulation of
mitochondria with tBid.
Next, we determined whether Omi, like Smac, promotes
caspase-9 activity in HEK293 S100 extracts in the presence of
XIAP. To measure the caspase-9 activity in these extracts, we
added 35S-labeled procaspase-3 to the S100 extracts and stim-
ulated the extracts with cytochrome c and dATP. As shown in
Fig. 5a, mature WT Omi or the S306A mutant was able to
promote procaspase-3 activation in the XIAP-containing S100
extracts almost to the same extent as Smac. The ability to
potentiate procaspase-3 activation was dependent on the AVPS
motif of Omi, since deletion of this motif abolished its caspase-
promoting activity. These observations suggest that Omi, like
Smac, is able to disrupt the interaction of caspase-9 with XIAP
in the S100 extracts to promote procaspase-3 activation.
To determine whether release of Omi can potentiate apopto-
FIG. 4. Omi is released together with Smac and cytochrome c
from the mitochondria during apoptosis. a, human Jurkat T-cells
and HL-60 cells were treated with staurosporine (2 M) for the indi-
cated periods of time, the cells were collected and lysed, the cytosolic
extracts were bound to GST-BIR3, and the bound proteins were ana-
lyzed by immunoblotting with Omi and Smac antibodies (first and
second panel, respectively). The cytosolic extracts were also analyzed by
immunoblotting with cytochrome c (third panel) or caspase-3 (fourth
panel) antibodies. b, Jurkat cells were treated with TRAIL (1 g/ml) for
the indicated periods of time; the cells were collected and lysed; and the
cytosolic extracts were analyzed by immunoblotting with Omi, Smac,
and cytochrome c antibodies. c, immunofluorescence confocal micros-
copy of untreated or staurosporine-treated (1 M, 5 h) HeLa cells or
untreated or TRAIL-treated (1 g/ml) MCF-7 cells stained with Omi-
specific antibody. Note the punctate perinuclear staining in the un-
treated cells and the diffused staining in the treated cells. d, isolated
293 mitochondria were incubated with or without purified tBid (350 nM)
as indicated. The supernatants (S) and mitochondrial pellets (P) were
separated by centrifugation and analyzed by immunoblotting with Omi,
Smac, cytochrome c, and cytochrome c oxidase antibodies.
FIG. 5. Omi can potentiate caspase activation and apoptosis. a,
293T S100 extracts (20 g) were mixed with purified XIAP (50 ng) and
then stimulated with cytochrome c (0.5 g) plus dATP (1 mM) in the
presence of increasing amounts (10, 50, and 300 ng, respectively) of
purified mature WT Omi, Omi-AVPS, Omi-S306A, or mature Smac in
a 10-l reaction volume. S100 extracts without XIAP () were used as
controls. The reactions were carried out in the presence of 35S-labeled
procaspase-3 for 1 h and then analyzed by SDS-polyacrylamide gel
electrophoresis and autoradiography. Fifth lane, S100 extracts incu-
bated with 300 ng of WT Omi without XIAP. b, HeLa cells were trans-
fected with an empty vector or constructs encoding a C-terminally
FLAG-tagged wild type- or S306A Omi precursor together with
pEGFP-N1 plasmid (CLONTECH) at a 4:1 ratio. The AVPS motif in the
S306A mutant Omi precursor is also mutated to the VVAS sequence to
prevent binding to IAPs. 24 h after transfection, the cells were treated
with the indicated doses of staurosporine for 5 h, and the percentages of
GFP-positive apoptotic cells were determined. Inset, expression of ma-
ture Omi wild type and Omi S306A mutant in the transfected cells as
determined by immunoblotting with FLAG antibody. c, MCF-7 and
HeLa cells were transfected with a full-length antisense Omi cDNA ()
in a pRSC-GFP double expression vector or an empty pRSC-GFP vector
(). 72 h after transfection, the cells were treated with Fas (500 ng/ml,
5 h), TRAIL (1 g/ml, 5 h), or staurosporine (1 M, 5 h) as indicated, and
the percentages of GFP-positive apoptotic cells were determined by
fluorescent microscopy after staining with 4,6-diamidino-2-phenylin-
dole and propidium iodide.















sis, we transfected human HeLa cells with the Omi precursor
and stimulated the cells with different doses of staurosporine.
We reasoned that treatment with staurosporine should release
the overexpressed Omi from the mitochondria, thereby enhanc-
ing apoptosis. As shown in Fig. 5b, transiently expressed wild
type Omi did not induce significant apoptosis in the absence of
staurosporine. However, at 500 nM staurosporine, 43% of the
Omi-transfected cells showed signs of apoptosis compared with
20% in the case of the vector-transfected cells. With higher
concentrations of staurosporine, increased apoptosis was ob-
served in the Omi-transfected cells compared with the vector-
transfected cells. No apoptosis potentiation was observed with
an active site Omi precursor mutant, which also has a mutant
VVAS sequence instead of the AVPS motif. These observations
suggest that release of Omi by an apoptotic stimulus such as
staurosporine enhances cell death.
To determine whether endogenous Omi plays a role in cell
death, we transfected MCF-7 and HeLa cells with an antisense
Omi cDNA to reduce the expression of Omi in the transfected
cells. As shown in Fig. 5c, the Omi antisense cDNA reduced
significantly (30–35%) the sensitivity of the transfected cells to
apoptotic stimuli. These results suggest that Omi participates
together with other apoptotic factors in the overall sensitivity
of cells to apoptosis.
Since Omi possesses both serine protease and IAP binding
activities, we wanted to determine the contribution of each of
these activities separately toward its overall proapoptotic ac-
tivity. To determine the contribution of the serine protease
activity of Omi toward its proapoptotic activity, it was neces-
sary to express cytosolic protease-active and -inactive forms of
Omi that do not bind IAPs in cells. This was achieved by
expressing active and inactive (S306A) Omi-GFP fusion pro-
teins without the MTS (M-Omi-GFP and M-Omi-S/A-GFP, re-
spectively) in MCF-7 cells (Fig. 6a). We found that these forms
of Omi do not bind XIAP-BIR3 (Fig. 6e, first lane) because the
initiator methionine before the AVPS motif is not removed in
transfected human cells (not shown). Nevertheless, only the
serine protease-active M-Omi-GFP, but not the inactive M-
Omi-S/A-GFP, was able to induce cell death in MCF-7 cells
(Fig. 6b). Similar results were obtained with cytosolic Omi
variants lacking the AVPS motif (data not shown). Of note, the
Omi-killing activity was independent of the cellular caspase
activity, since inhibition of cellular caspases with zVAD-FMK,
XIAP, XIAP-BIR3, or caspase-9-DN did not block the ability of
M-Omi-GFP to kill these cells. Consistent with these results,
M-Omi-GFP was also able to induce cell death in Apaf / and
caspase-9 / mouse embryo fibroblasts (Fig. 6c). These re-
sults indicate that Omi can induce cell death in mammalian
cells independent of caspases, Apaf-1, or IAPs via its serine
protease activity.
FIG. 6. Dual role of Omi in cell death. a, schematic diagrams of the Omi-GFP and GFP-IETD-Omi constructs used to assay the ability of Omi to
induce apoptosis or to enhance apoptosis by other stimuli. The Omi fusion proteins that induce or enhance apoptosis are marked with a plus sign, and
those that do not are marked with a minus sign. b, MCF-7 cells were transfected with M-Omi-S/A-GFP or pEGFP-N1 alone or M-Omi-GFP together
with empty vector or expression construct encoding XIAP, XIAP-BIR3, or caspase-9DN. The cells were also transfected with the M-Omi-GFP expression
construct in the presence of zVAD-FMK (20 M). 36 h after transfection, the percentages of apoptotic cells were determined as described under
“Experimental Procedures.” c, Apaf-1 / or caspase-9 / mouse embryo fibroblasts were transfected with pEGFP-N1, M-Omi-GFP, or M-Omi-S/
A-GFP. 36 h after transfection, the percentages of apoptotic cells were determined. d, MCF-7 and 293T cells were transfected with pEGFP or
M-Omi-Flag, GFP-IETD-AVP (AVP), or GFP-IETD-SSA (SSA) expression constructs in the presence or absence of zVAD-FMK (20 M). 24 h after
transfection, the cells were harvested, and their extracts were fractionated and analyzed by immunoblotting with FLAG-horseradish peroxidase
antibody. M-Omi-FLAG is similar to the M-Omi-GFP shown in a, except that the GFP tag was replaced with FLAG tag. e, 293T cells were transfected
with the indicated expression constructs. 24 h after transfection, the cells were harvested, and their extracts were precipitated with GST-BIR3. The
extracts and the precipitated proteins were immunoblotted with FLAG-horseradish peroxidase antibody. pOmi-FLAG, C-terminal FLAG-tagged Omi
precursor (only the mature Omi can be seen). f, MCF-7 cells were transfected with the indicated expression constructs. 24 h after transfection, the cells
were left untreated () or treated with TRAIL () for 16 h. The percentage of round apoptotic cells was determined.















We next tested the contribution of the IAP binding activity of
Omi to its killing activity. To do that, we replaced the MTS of
Omi with a GFP-IETD sequence and mutated its active site
Ser306 to Ala (Fig. 6a, GFP-IETD-AVP). Of note, the presence of
the IETD sequence between GFP and Omi-S/A allowed caspase-
dependent cleavage at the IETD site after the Asp residue and
release of mature Omi-S/A in the cytosol of the transfected 293
and MCF-7 cells (Fig. 6d). This mature Omi-S/A was able to
bind the GST-BIR3 fusion protein (Fig. 6e), indicating that it is
correctly processed to expose its AVPS motif. Consistent with
this result, very little or no processing at the IETD site was
observed in the cytosolic extracts of these cells in the presence
of the pancaspase inhibitor zVAD-FMK (Fig. 6d). As shown in
Fig. 6f, expression of the GFP-IETD-AVP fusion protein in
MCF-7 cells enhanced TRAIL-induced apoptosis in these cells
severalfold above the GFP-transfected control cells. This activ-
ity was dependent on the AVPS motif, since mutation of the
AVPS motif to an SSAS motif (GFP-IETD-SSA) abolished the
apoptotic enhancement activity of Omi-S/A and the ability to
bind to BIR3. These results indicate that the IAP binding
activity of Omi represented by its AVPS motif plays a signifi-
cant role in its ability to potentiate apoptosis independent of its
protease activity. Taken together, Omi not only can induce cell
death through its serine protease activity but also via its ability
to bind and neutralize IAPs.
Our observations reveal a new level of regulation of apoptosis
by the mitochondria. The identification of Omi as a mitochon-
drial serine protease that can also bind and neutralize IAPs
adds to the list of proapoptotic proteins such as cytochrome c,
apoptosis-inducing factor, Smac, and endonuclease G (18–21),
which are released from the mitochondria during apoptosis,
and emphasizes the importance of the mitochondria in the cell
death pathway of eukaryotic cells. Because Omi is a serine
protease, its sequestration in the mitochondria protects
healthy cells from its proteolytic activity. However, when cells
become damaged, they release Omi, together with other inter-
mitochondrial membrane space proteins, into the cytoplasm,
where it could cause irreparable proteolytic damage to impor-
tant structural and regulatory components of the cell. In addi-
tion, mature Omi could play a role as an IAP inhibitor in the
caspase-dependent apoptotic pathway by binding to the BIR3
domain of XIAP and disrupting its interaction with the acti-
vated caspase-9. This activity may complement the activity of
Smac by neutralizing more IAPs in the cytoplasm, resulting in
more caspase activation in cells undergoing apoptosis.
While the importance of caspases in cell death is well estab-
lished, a large body of evidence suggests that other types of
proteases might also be important (22, 23). For example, inhib-
itors of serine proteases such as diisopropyl fluorophosphate,
1-chloro-3-tosylamido-7-amino-2-heptanone, and L-1-tosyl-
amido-2-phenylethyl chloromethyl ketone can delay or fully
inhibit distinct steps of the cell death pathway (22, 24). More-
over, inhibition of caspases generally delays but does not com-
pletely block cell death by some cell death stimuli. Thus, the
serine protease activity of Omi could be responsible for the
noncaspase-dependent cell death observed in many model
systems.
Although there is now clear evidence that cytochrome c,
apoptosis-inducing factor, and endonuclease G contribute to
the demise of the cell when released from the mitochondria into
the cytoplasm or nucleus, the real physiological function of
these proteins is far from being killer proteins. In fact, these
proteins are essential for normal mitochondrial function and
cell survival. This is most likely true for Omi. Omi belongs to
the heat shock response serine proteases (HtrAs), which have
been shown in bacteria to be essential for cell survival at high
temperature (25). Omi and its related family members could
control protein stability and turnover under thermal, osmotic,
pH, and other stress conditions. Interestingly, an Omi-related
protease has been identified in the chloroplast of Arabidopsis
thaliana, suggesting that these proteases play important roles
in organellar biogenesis and function (26). Although our data
clearly show that Omi is localized predominantly in the mito-
chondria, recent data indicated that Omi is also localized in the
nucleus of stressed cells (16), suggesting that Omi perhaps
could translocate from mitochondria to the nucleus after stress.
In conclusion, the release of Omi from the mitochondria
might represent a novel cell death pathway that has not yet
been fully appreciated. Omi could bind and inhibit the cellular
IAPs, thus potentiating the caspase-dependent apoptotic path-
way. More importantly, Omi could induce cell death independ-
ent of caspases via its serine protease activity. The targeted
disruption of the Omi gene in the future should allow the
determination of the precise role of Omi in cell death and
survival.
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